DJIA 18,288.63 155.93 0.86%
NASDAQ 5,008.10 44.57 0.90%
S&P 500 2,117.39 12.89 0.61%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)



company name or ticker

Sarepta Therapeutics (SRPT): Heavy Pre-Market Activity

Benzinga's Top #PreMarket Gainers

BioMarin Acquires Prosensa in Deal Valued Up to $840 Million

Celldex Therapeutics To Enter Talks With FDA

Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog

Ebola Stock Short Interest Surprise

Sarepta Therapeutics' (SRPT) CEO Chris Garabedian on 23rd Annual Credit Suisse Healthcare Conference

Sarepta Therapeutics' (SRPT) CEO Chris Garabedian on 23rd Annual Credit Suisse Healthcare Conference Call Transcript

Sarepta Q3 Loss Narrower-Than-Expected, Eteplirsen in Focus - Analyst Blog

Why Sarepta Therapeutics Inc. Stock Imploded in October

Sarepta Therapeutics was one of the worst biotech stocks in October. Find out why its shares lost nearly one-quarter of their value and whether or not they're poised for a rebound.

Sarepta Therapeutics (SRPT) Q3 2014 Results - Earnings Call Webcast

See More Articles...